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ABSTRACT Pulmonary hypertension (PH) with complicating chronic lung diseases and/or hypoxia falls
into group 3 of the updated classification of PH. Patients with chronic obstructive lung disease (COPD),
diffuse lung disease (such as idiopathic pulmonary fibrosis (IPF)) and with sleep disordered breathing are
particularly exposed to the risk of developing PH. Although PH in such a context is usually mild, a minority
of patients exhibit severe haemodynamic impairment, defined by a mean pulmonary arterial pressure
(mPAP) of ⩾35 mmHg or mPAP values ranging between 25 mmHg and 35 mmHg with a low cardiac index
(<2 L·min−1·m−2). The overlap between lung parenchymal disease and PH heavily affects life expectancy in
such a patient population and complicates their therapeutic management. In this review we illustrate the
pathological features and the underlying pathophysiological mechanisms of pulmonary circulation in chronic
lung diseases, with an emphasis on COPD, IPF and obstructive sleep apnoea syndrome.
Introduction
A wide variety of pulmonary diseases with obstructive and/or restrictive lung function impairment may be
associated with pulmonary hypertension (PH). In the updated clinical classification of PH [1], these are
placed in group 3, “PH owing to lung diseases and/or hypoxia” (table 1). In this group of diseases, the
presence and severity of PH impact unfavourably on prognosis and thus have a bearing on treatment
planning. Also, elucidation of the responsible pathogenetic mechanisms may lead to the development of
rational and targeted therapies, which are not yet currently available.
PH is defined as a mean pulmonary arterial pressure (mPAP) of at least 25 mmHg at rest, as measured by
right heart catheterisation [2]. According to the current classification, the consensus definition for PH in
pulmonary parenchymal diseases is determined by an mPAP value of ⩾25 mmHg, while severe PH is
qualified by mPAP values ⩾35 mmHg, or mPAP ⩾25 mmHg and ⩽35 mmHg but with a low cardiac
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index (<2 L·min−1·m−2) [3]. In idiopathic pulmonary fibrosis (IPF), such severe PH carries a very poor
prognosis.
Biopsy pathology has no significant role to play in the demonstration of PH in this group of diseases, or in
the assessment of its severity, but it does provide some angle on pathogenesis. Various distinct histological
patterns of hypertensive pulmonary vascular disease have been identified in past decades, and these can be
linked, to some extent, to different clinical contexts [4]. It is plausible that these various patterns and the
differences between them reflect differences in pathogenesis and are, therefore, of potential therapeutic
interest. In the rather heterogeneous subgroup of “PH owing to lung diseases and/or hypoxia”, the
vascular pathology is heterogeneous as well.
However, our knowledge of histopathology is limited, because it is largely restricted to lung explant and
autopsy specimens, except for “pure” hypoxic PH in the absence of pulmonary parenchymal disease,
which is easily produced in experimental animals and has its human counterpart in people living at high
altitudes, as well as a limited number of conditions of hypoventilation that are unassociated with
pulmonary parenchymal disease (see below).
The situation is more complex in lung diseases that, apart from resulting in lung hypoxia, also have
associated airway or parenchymal inflammatory or fibrosing disease. The blood vessels of any tissue in the
body affected by inflammation and fibrosis display remodelling and the lung is no exception. Such
vascular changes are usually a combination of intimal fibrosis with medial and adventitial thickening.
Occluding thrombi are not uncommon.
In this review, we discuss the pathology of vascular disease in this heterogeneous group of lung diseases,
with special emphasis on possible pathogenetic mechanisms.
“Pure” hypoxic PH: clinical data
In contrast to the systemic circulation, where tissue hypoxia induces arteriolar vasodilatation, hypoxia of lung
tissue results in arterial vasoconstriction [5] and, if the hypoxia persists over long periods of time, induces
increased muscle in arterial walls, especially of very small branches. This response is presumably beneficial in
the case of unequal ventilation of lung tissue, but it results in PH when hypoxia globally affects the lungs.
Hypoxic PH is readily produced in animals exposed to decreased air pressure or decreased oxygen
concentration in ambient air. In humans, a very similar situation exists in chronic mountain sickness
(Monge’s disease), a potentially lethal form of hypoxic pulmonary hypertensive disease unassociated with
any pulmonary parenchymal disease. Not surprisingly, hypoventilation, such as may result from muscle
weakness, thoracic deformities and morbid obesity, results in a similar remodelling of pulmonary arteries
and PH. In addition, an increased haematocrit may be associated with increased likelihood of thrombosis,
so that thromboembolic events, either clinically manifest or occult, may contribute to the PH. Such
post-thrombotic vascular disease is hallmarked histologically by focal lesions, which constitute the
remnants of organised and recanalised thrombi; (often eccentric) patches of marked arterial intimal
fibrosis, and colander lesions; and organised and recanalised thrombi containing multiple lumina.
Hypoxic pulmonary vasoconstriction is the result of different mechanisms, ranging from a direct effect of
hypoxia on smooth muscle vascular cells [6, 7], to a decreased release of endothelium-derived vasodilators [8]
TABLE 1 Classification of pulmonary hypertension, group 3
1 Pulmonary arterial hypertension
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
1′′ Persistent pulmonary hypertension of the newborn
2 Pulmonary hypertension owing to left heart disease
3 Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4 Chronic thromboembolic pulmonary hypertension
5 Pulmonary hypertension with unclear multifactorial mechanisms
Data from [1].
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and increased secretion of vasoconstrictors [9, 10]. Rodents exposed to chronic hypoxia develop
medial thickening of small pulmonary arteries and muscularisation of arterioles, which normally lack a
muscle coat, resulting in reversible PH [11, 12]. Similar vascular structural changes have been found in the
lungs of healthy high-altitude dwellers [13]. These changes, which are the consequence of hypoxic pulmonary
vasoconstriction combined with an increased fluid shear stress, are largely reversible when the hypoxic
stimulus is removed [14]. Chronic hypercapnia is also a common finding in patients carrying hypoxic lung
disease [15]. Nevertheless, the effect of carbon dioxide on pulmonary vascular tone is controversial, with
experimental data providing an effect of both vasoconstriction and vasodilatation [16, 17].
Obstructive sleep apnoea syndrome (OSAS) is characterised by recurrent episodes of upper airway
obstruction during sleep, resulting in periodic hypoxia, sleep fragmentation and day-time sleepiness. This
condition is associated with increased cardiovascular mortality [18, 19]. There is a strong relationship
between OSAS and systemic arterial hypertension [20, 21] with ischaemic heart disease, atrial fibrillation
and stroke [22–27]. Data about the occurrence of PH in pure, severe OSAS are extremely scant and
indicate that severe PH rarely develops [28]. In addition, some results seem to indicate the reversibility of
PH after treatment of the sleep disorder [29, 30].
The mechanisms underlying these associations have only been elucidated incompletely. Excessive
sympathetic activity, increased oxidative stress, metabolic alterations and inflammation triggered by
intermittent hypoxia are all thought to play a role. Indeed, intermittent hypoxia is known to induce the
expression of a variety of inflammatory mediators, including nuclear factor-κB (NF-κB) cells, tumour
necrosis factor (TNF)-α, interleukin (IL)-8 and IL-6 [31–33].
Intermittent hypoxia resulting from sleep apnoea can stimulate the carotid body, the principal chemoreceptor
detecting the variations of blood oxygen concentration, resulting in increased sympathetic activity and raised
blood pressure during apnoeic episodes [34–36]. Rodents (rats and mice) that have been exposed to
intermittent hypoxia manifest an enhanced carotid body chemoreflex response when re-exposed to acute
hypoxia [37, 38]. As is the case with high-altitude PH, hypoxia triggers vasoconstriction of the lung vessels
and may induce vascular remodelling characterised by the thickening of the muscular layer of small
pulmonary arteries. In addition, left heart dysfunction, which may arise in OSAS, may lead to increased
pulmonary venous pressure, which induces muscularisation of pulmonary veins.
The pathogenetic mechanisms of chronic hypoxia-induced vascular changes are still incompletely
understood. In pulmonary arterial smooth muscle cells, hypoxia can lead to the shutdown of K+ channels,
resulting in membrane depolarisation and increased Ca2+ intake. The raised cellular Ca2+ concentration
results in sensitisation of the cytoplasmic contractile machinery, leading to arterial vasoconstriction [7].
Hypoxia also generates a stress response in endothelial cells, resulting in the expression of hypoxia
inducible factor (HIF)-1α, HIF-2α and peroxisome proliferator-activated receptor gamma coactivator
(PGC)-1α, which are pivotal transcriptional regulators [39, 40]. The transcription factor HIF-1 is a major
regulator of cell oxygen homeostasis that, under hypoxic conditions, shifts cell metabolism towards
anaerobiosis [41]. In addition, HIF-1 induces transcription of EPO and VEGF, thus increasing blood oxygen
carriage capacity and promoting angiogenesis in hypoxic areas [42, 43]. Known HIF target genes include
growth factors such as vascular endothelial growth factor (VEGF) and vascular endothelial growth factor
receptor (VEGFR)2, pro-inflammatory cytokines such as stromal cell-derived factor (SDF)1 and chemokine
receptor type (CXCR)4, glucose metabolic enzymes such as glucose transporter (Glut)-1 and hexokinase
(HK)2, and the activation of pro-survival cellular pathways such as NF-κB signalling. In hypoxic lung
tissue, macrophages release hypoxia-induced mitogenic factor (HIMF), which promotes inflammation and
angiogenesis via VEGF and its receptor VEGFR2 [44]. The cytokines released by vascular cells and
macrophages may also recruit fibrocytes exhibiting a “inflammatory” phenotype, characterised by the
expression of IL-1, IL-6, regulated on activation, normal T-cell expressed and secreted (RANTES), SDF-1
and its receptor CXCR4, osteopontin and the integrin receptor ανβ3 [45]. The role of IL-6 as a mediator of
PH in rodents exposed to chronic hypoxia has been well documented [46]. The overexpression of IL-6 in
the lungs of mice exposed to chronic hypoxia results in severe PH, characterised by vascular obliterative
lesions [47]. Moreover, the increased secretion of IL-6 in hypoxic lungs results in decreased expression of
bone morphogenetic protein receptor (BMPR)2, which is mutated in up to 70% of patients with heritable
PH [48, 49]. Hypoxic stress also generates endothelial cell production of reactive oxygen species (ROS) and
nitrogen species [50], which influence the pulmonary vasomotor state [51]. Thus, chronic hypoxia has an
effect on the expression levels of a plethora of vasoconstrictive and inflammatory mediators.
PH in COPD and interstitial lung disease: clinical data
In chronic obstructive pulmonary disease (COPD), the prevalence of PH closely parallels the severity of
the condition, with up to 90% of patients having a mPAP of over 20 mmHg at rest. Although PH is
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usually mild, about 1% of patients have severe PH, with mPAP values between 35 and 40 mmHg [52, 53].
The presence and severity of PH in COPD have a substantial impact on survival [53, 54].
In idiopathic pulmonary fibrosis (IPF), mPAP values >25 mmHg are detected in a proportion of patients
ranging from 8.1% to 14.9% upon initial examination [55, 56]. In advanced and end-stage disease, these
figures have risen to about 50–60% [57, 58]. Clinical, functional and biological indicators of PH in IPF are
worsening dyspnoea, impaired gas exchange at rest and low diffusing capacity of the lung for carbon
monoxide.
PH is a significant prognostic factor in IPF [56], and the prognostic impact of PH in IPF is related to the
severity of PH and pulmonary vascular resistance (PVR) [59] and to a cardiac index below
2.4 L·min−1·m−2 [60]. Patients with combined emphysema and pulmonary fibrosis are also at high risk to
develop PH, which is found in 30–50% of these patients [61] and may be disproportionally severe. PH has
also been documented as a rare complication occurring in cystic fibrosis [62] and bronchopulmonary
dysplasia [63].
The workup for PH assessment in chronic lung disease first includes non-invasive mPAP assessment by
echocardiography. The direct measurement of PH in chronic lung diseases by right heart catheterisation is
required when lung transplantation is considered, or when a disproportional clinical deterioration
compared to ventilatory impairment is noted, or in order to validate the diagnosis of PH in view of patient
enrolment in a clinical trial or to confirm left heart dysfunction and to adjust therapy.
Pathogenesis of PH in COPD
The pathophysiology of COPD is hallmarked by irreversible airflow obstruction. Often, there is some
degree of inflammation of the airway walls. The inflammation usually represents a response to protracted
exposure to toxic substances, such as those present in tobacco smoke. The inflammatory response is
marked by increased numbers of macrophages and T-helper lymphocytes in lung tissue. These are a
source of a variety of cytokines and growth factors, such as leukotriene B4, CXC chemokines, IL-1β and
IL-6 and profibrogenic transforming growth factor (TGF)-β. In addition, cigarette smoke and small airway
inflammation result in oxidative stress, leading to an increased release of proteases by neutrophils and
macrophages and the inactivation of antiproteases, such as α1-antitrypsin and secretory leukoprotease
inhibitors. The smouldering inflammation leads to airway wall thickening, including an increase in airway
wall smooth muscle and hyperplasia of bronchial glands, and is accompanied by increased mucous
secretion and ciliary dysfunction of the surface epithelium, all contributing to airflow obstruction. The
augmented secretion of bronchial mucus is the result of increased numbers of goblet cells within the
surface epithelium and of hyperplasia of submucosal glands. The bronchial inflammation may also induce
squamous metaplasia and ciliary dysfunction, impeding the clearance of bronchial secretions. The airflow
obstruction following the stagnation of mucous secretions progressively leads to air trapping during
expiration, resulting in decreased lung capacity. The main airflow obstruction occurs in airways under
2 mm in diameter, where pathological changes are designated respiratory bronchiolitis–interstitial lung
disease (RB-ILD). The RB is characterised by the accumulation of macrophages within the respiratory
bronchiole and adjacent alveoli and by inflammation with mild thickening of the bronchiolar wall and
peribronchiolar alveoli [64].
PH in patients with COPD is the consequence of vasoconstriction as well as structural changes to the
vessel walls. The impediments to gas exchange in COPD generate lung tissue hypoxia and hypoxic
pulmonary vasoconstriction and remodelling, as outlined in the discussion on high-altitude PH, above.
Destruction of the lung parenchyma and the increased airway resistance due to airway wall thickening and
bronchial luminal obstruction with mucoid secretions, all contribute to lung hypoxia in COPD [65]. As
would be expected, the chronic pulmonary hypoxia in COPD leads to increased medial smooth muscle,
especially in small arterial branches [66] (figure 1). In patients with COPD, the hypoxia-induced
haemodynamic changes, in conjunction with exposure to toxic agents, engender irreversible vascular
structural alterations, characterised by muscularisation of the normally non-muscularised arterioles, as well
as medial thickening and neointimal lesions of small and medium-sized pulmonary arteries. Neointimal
lesions are characterised by extracellular matrix deposition and proliferation of cells phenotypically similar
to smooth muscle cells (SMCs), designated “smooth muscle-like cells” [67, 68]. Smooth muscle-like cells
express α-smooth muscle actin and vimentin, but not desmin, and probably represent a subset of
phenotypically immature SMCs [69, 70] (figure 2). They are commonly oriented longitudinally along the
vessel lumen, rather than in a circular orientation. Medial hypertrophy of arteries and muscularisation of
arterioles are observed in pre-acinar and intra-acinar small pulmonary arterial branches. In severe PH,
COPD larger pulmonary arteries also display some degree of medial hypertrophy as well as intimal
laminar fibrosis. The occurrence of vascular remodelling in COPD is thought to be related to the synergic
action of tobacco smoke and hypoxia. Vascular changes have been documented in non-hypoxaemic COPD
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patients, suggesting that the latter can develop independently of hypoxia-induced vasoconstriction. It
should be borne in mind, however, that tissue hypoxia may be present focally, in hypoventilated lung
areas, so hypoxia-induced haemodynamic changes may occur in the absence of systemic hypoxaemia [71].
In advanced COPD, destruction of the pulmonary vessels is usually mentioned as a contributor to the
elevation of mPAP [52]. Nevertheless, studies correlating computed tomography lung tissue density with
haemodynamics did not provide any significant association [72, 73]. Nonetheless, it is generally assumed
that the capacity of pulmonary vessels for haemodynamic adaptation may be further impaired in the
presence of parenchymal destruction, exposing patients to exercise-induced PH [74].
Hypoxia is not a unique contributor to the development of vascular changes in COPD. Indeed, as indicated
above, pulmonary vascular remodelling may also be observed in non-hypoxaemic mild COPD and oxygen
therapy is usually insufficient to reverse PH in COPD patients. The sum of these two observations indicates
that other mediators are involved in vascular alterations [75, 76]. Cigarette smoking may result in
endothelial dysfunction, with enhanced production and release of growth factors and affluence of
FIGURE 1 Small pulmonary arteries exhibiting irregular intimal and medial thickening within emphysematous
lung parenchyma. Haematoxylin–eosin–saffron staining. Scale bar=100 µm.
a) b)
FIGURE 2 a) Actin immunostaining of a remodelled small pulmonary artery. The neointima is thickened by the affluence of cells phenotypically
similar to smooth muscle cells (SMC-like cells), expressing actin. b) Desmin immunostaining of the same remodelled pulmonary artery. The
neointimal SMC-like cells do not express desmin, unlike medial smooth muscle cells. Both images courtesy of P. Dorfmüller, Hôpital Marie
Lannelongue, Le Plessis Robinson, France. Scale bars=100 µm.
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inflammatory cells, leading to smooth muscle cells proliferation and vessel wall thickening [77–79]. The
biological pathways disrupted by tobacco smoke are largely unexplored, but it is thought that they may be
related to oxidative damage [80]. ROS are effective in destroying lung parenchyma by direct damage as well
as by inducing inflammation [81]. Nitric oxide (NO) may combine with superoxide (O2−) to form the
strong oxidant peroxynitrite (ONOO−) [82]. ONOO− may induce both apoptosis and low proliferation in
alveolar epithelial cells [83]. The impact of ONOO− on cell proliferation and survival is achieved via c-Jun
N-terminal kinases ( JNK) and Src (sarcoma-family kinases) phosphorylation and upregulation of Rtp801
[83]. Moreover, ONOO− can also react with protein tyrosine residues to form the nitrotyrosine, which is
considered a marker of cell damage and is increased in COPD lungs [84, 85]. Tobacco smoke also generates
products of lipid peroxidation, such as F2-isoprostanes, 4-hydroxy-2-nonenal, acrolein and
malondialdehyde, which trigger cellular redox signalling effects. The oxidative stress can influence primal
cell signalling and induce nuclear histone modifications, enhancing the tissue inflammatory response.
Investigations of the impact of tobacco smoke on lung circulation in animals have confirmed the hypothesis
that tobacco exposure induces muscularisation of pre-capillary vessels and that this happens before the
occurrence of emphysema [86, 87]. Nevertheless, there is no doubt that hypoxia plays a decisive role in
COPD vascular changes leading to PH. As airflow obstruction increases, the effects of hypoxaemia on
pulmonary circulation may add to the detrimental effects of tobacco smoke.
Pathogenesis of PH in IPF
IPF is characterised by the progressive scarring of lung tissue, which leads functionally to the deterioration of
gas exchange capacity through a restrictive lung function abnormality, in combination with shunting of
blood through the vessels running by the fibrotic lung. Usual interstitial pneumonia (UIP) is the
histopathological equivalent of IPF. UIP is characterised by a heterogeneous distribution of the fibrosis,
predominating in subpleural and basal zones, and results from the accumulation and confluence of fibrosis,
which characteristically begins as so-called fibroblast foci, small foci of subepithelial fibroblasts and increased
matrix. Scarred areas are juxtaposed next to conserved parenchymal fields, without intervening transition
zones. Areas of “active” ongoing fibrosis (represented by fibroblastic foci) coexist with areas of hyaline
fibrosis within the scarred regions. Fibroblastic foci are characterised by aggregates of actively proliferating
myofibroblasts within a myxoid matrix, oriented with the long axis parallel to the long axis of the alveolar
septa. Such aggregates are thought to derive from the organisation of small interstitial exudates. Fibroblastic
foci can be readily identified because of their light-staining matrix, rich in proteoglycans, contrasting with
the “dark-staining” fibrosis or honeycomb areas. “Honeycomb” changes, which consist of large airspaces
surrounded by fibrotic tissue, covered by bronchiolar-type epithelium or hyperplastic type 2 pneumocytes,
result from lung architectural restructuring following alveolar injury. A mild inflammatory infiltrate,
consisting of small lymphocytes, plasma cells and sometimes neutrophils and eosinophils, is often seen
within fibrotic or honeycomb areas. Remodelling of pulmonary vessels is observed both within the fibrotic
areas and in unscarred lung parenchyma (figure 3). In the fibrotic zones, small pulmonary arteries display
substantial intimal fibrosis and medial hypertrophy. The pulmonary veins are also affected by remodelling,
a) b)
FIGURE 3 a) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). The narrowing of the vascular lumen is the result
of both intimal fibrosis and medial smooth muscle increase. Haematoxylin–eosin–saffron staining. Scale bar=250 μm. b) Remodelled small
pulmonary arteries outside fibrosis in usual interstitial pneumonia lung. Haematoxylin–eosin–saffron staining. Scale bar=200 μm.
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exhibiting luminal narrowing by an intimal fibrosis. In architecturally conserved lung zones, some
remodelling is seen in pulmonary venules, exhibiting luminal occlusion by acellular fibrous tissue. Such a
finding often coexists with alveolar capillary multiplication and muscularisation of pulmonary arterioles [88].
PH in IPF is increasingly prevalent as IPF progresses. In view of the histological features mentioned above,
the occurrence of PH in IPF cannot be explained solely by hypoxic vasoconstriction and the loss of
capillary bed through the scarring tissue. To improve the therapeutic management of IPF-associated PH,
there is a need to understand the pathobiology of the fibrotic process itself, as well as of the associated
vascular remodelling. The density of blood vessels is low in scarred lung regions, while the non-fibrotic
tissues at the edge of such regions are richly vascularised. In scarred areas, complex biological processes
perturbing the vessels’ homeostasis are ongoing. Notably, the imbalance between angiogenetic mediators
(such as VEGF) and angiostatic factors (such as pigment epithelium-derived factor (PEDF)) dramatically
contributes to pulmonary circulation restructuring, with an increased risk of developing PH. In addition,
the effects of oxidative substances and of paracrine molecules released in scarring areas may trigger cellular
stress responses and pathobiological processes such as an endothelial to mesenchymal transition,
participating in the vascular remodelling.
The pathobiology of vascular remodelling in IPF is complex, and diverse molecules are involved. Such
molecules are of potential interest as biomarkers of the progression of the disease and as potential targets
of novel therapies.
TGF-β is a master regulator of extracellular matrix deposition and fibroblasts proliferation, and it is an
acknowledged profibrogenic factor. In the lung, TGF-β is produced by macrophages as well as epithelial cells
and fibroblasts. It is secreted in the form of an inactive precursor that is activated by proteolytic cleavage.
Smad2/3, mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and Rho GTPase
pathways are activated by interaction of the TGF-β receptor with its ligand. Notably, activation of the Smad
pathway appears to be crucial for fibroblast proliferation and extracellular matrix (ECM) production
culminating in fibrosis [89]. TGF-β influences the inflammatory response through the inhibition of immune
cell proliferation [90], and is also involved in angiogenesis in a dose-dependent manner [91]. It promotes
endothelial cell (EC) apoptosis, differentiation and vascular smooth muscle cell (VSMC) recruitment at high
doses, while activating EC at low doses [92]. High TGF-β levels in fibrotic areas may indeed contribute to
local EC apoptosis, leading to vascular depletion and to an increase in muscularisation of the pulmonary
arteries. Indeed, apoptotic ECs in pulmonary fibrotic areas may release growth factors driving VSMC
proliferation, such as the platelet-derived growth factor (PDGF) [93–95]. Moreover, the depletion of ECs and
endothelial dysfunction in those areas may lead to a decreased production and dropping of vasodilators and
inhibitors of VSMC proliferation, such as prostacyclin and NO [95]. In parallel with such phenomena,
enhanced release of vasoconstrictors such as endothelin-1, angiotensin and thromboxane A2 is documented,
contributing to vascular remodelling and to the increase in mPAP [96, 97].
VEGF is a chief driver of angiogenesis, with a major role, also, in the homeostasis maintenance of the
vascular system. ECs need VEGF signalling for survival and proliferation, and VEGF inhibition leads to
capillary alveolar damage, resulting in emphysema. VEGF expression is induced by hypoxia and TGF-β
stimulation. In lungs, VEGF is mainly secreted by macrophages, epithelial cells, ECs and mesenchymal cells
[98]. In IPF, VEGF is markedly reduced within fibrotic areas [99, 100], where its depletion is correlated with
EC apoptosis. The level of VEGF is also reduced in the bronchoalveolar lavage fluid of IPF patients.
PDGF is suggested to play a role in fibrosis progression and in pulmonary artery remodelling in IPF, by
promoting fibroblast and VSMC proliferation and migration, leading to excessive arterial muscularisation
and intimal fibrosis [101]. This finding is also sustained by investigations on experimental models [102]. It
is postulated that PDGF acts in an early stage of IPF vascular remodelling, because it can be detected in
ECs and VSMCs. PDGF is no longer found in lung vessels in late-stage disease [103]. PDGF could be a
relevant target for the inhibition of fibrogenesis and vascular remodelling.
PEDF is found in lung mesenchymal cells, ECs and in bronchial cells. This molecule has a strong
angiostatic effect, inhibiting VEGF-induced angiogenesis and inducing EC apoptosis. PEDF can be
involved in lung fibrosis, by promoting fibroblast growth, because PEDF is found in the extracellular
matrix [104]. Moreover, PEDF inhibition may be an interesting therapeutic target.
Other potential molecular targets limiting fibrosis and vascular remodelling include endostatins,
endothelin-1 and angiotensin-II (ATII). In particular, endostatins have an angiostatic effect, through the
inhibition of VEGFR2 and matrix metalloproteinase 2 (MMP-2), and are potentially involved in pulmonary
artery remodelling in IPF [105, 106]. Those molecules are generated by the injured lung epithelium from
the proteolytic cleavage of collagen XVIII, and their levels in lung tissue seem to be correlated to the degree
of lung parenchymal damage in IPF [107, 108]. Endothelin-1 has vasoconstrictive effects and is also an
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inductor of VSMC growth [97]. Although endothelin seems to be involved in IPF PH, the pharmacological
inhibition of its receptor did not result in sufficient clinical improvement [109]. The elevation of ATII
within fibrotic areas may therefore contribute to vascular remodelling, providing a solid rationale for
research focused on AT inhibition. Moreover, the relevance of ATII as a prognostic biomarker can also be
kept in consideration [110].
Conclusion
Diverse mechanisms are involved in the pathogenesis of pulmonary hypertensive vasculopathy in the
setting of parenchymal lung diseases and/or hypoxia. Pulmonary vasoconstriction, triggered by hypoxia,
represents the main pathogenetic mechanism in PH in high-altitude dwellers and in patients with sleep
disordered breathing. The persistence of vasoconstriction leads to structural changes in lung vasculature,
affecting mostly the small pulmonary arteries. In COPD, hypoxia, the exposure to tobacco smoke and the
loss of pulmonary vessels contribute to pulmonary haemodynamic impairment, through vascular
remodelling. Finally, PH in UIP is characterised by structural changes involving pulmonary vessels both
within the fibrotic areas and outside fibrosis. The biological mechanisms underlying vascular remodelling
in UIP are incompletely understood and encompass an altered balance between angiostatic and
angioproliferative mediators and the effects of both oxidative and paracrine molecules perturbing vascular
cell homeostasis. The occurrence of PH in parenchymal lung disease complicates the therapeutic attitude
and requires the guidance of specialist consultation.
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